CStone Pharmaceuticals logo

2616 - CStone Pharmaceuticals News Story

HK$9.59 -0.3  -2.6%

Last Trade - 9:08am

Sector
Healthcare
Size
Mid Cap
Market Cap £1.09bn
Enterprise Value £821.4m
Revenue £126.8m
Position in Universe 860th / 6152

BRIEF-Cstone Pharmaceuticals Says First-In-Class Registrational Study Of Sugemalimab Met Its Primary Endpoint In Stage III NSCLC

Fri 28th May, 2021 2:44am
May 28 (Reuters) - CStone Pharmaceuticals  2616.HK :
    * FIRST-IN-CLASS REGISTRATIONAL STUDY OF SUGEMALIMAB MET ITS
PRIMARY ENDPOINT IN STAGE III NSCLC
    * PLANS TO SUBMIT A NEW DRUG APPLICATION

Source text for Eikon:  ID:nCNWYkScNa 
Further company coverage:  2616.HK 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.